| Name | Title | Contact Details |
|---|
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.
bioStrategies Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clade Therapeutics is a well-funded cell therapy company developing novel cell-based medicines for the treatment of cancer and other devastating diseases. The company, located in the heart of Cambridge was recently launched by an exceptional group of academic leaders and successful bioentrepreneurs converging stem cell biology, immunology, regenerative medicine, and gene editing into the next-generation of stem cell-derived medicines.
OriGene Technologies is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.